Ionis Shares Fall About 27% After Tryngolza Sales Forecast Cut

Ionis Pharmaceuticals shares fell about 27% Monday after the company cut its 2026 sales forecast for Tryngolza, outweighing third-quarter results that exceeded revenue and earnings expectations.

Ionis now expects about $50 million in 2026 sales of Tryngolza (olezarsen), down from its previous forecast of $100 million to $110 million. The new target is about half the bottom of the earlier range. Tryngolza is a treatment for severe hypertriglyceridemia.

The forecast cut accompanied third-quarter results that beat expectations for both revenue and earnings. For the quarter ended Sept. 30, Ionis recorded $243 million in revenue and a $0.66 per-share loss under generally accepted accounting principles.

The revised outlook covers sales of Tryngolza for the full year. The $243 million revenue figure covers Ionis as a whole for the third quarter.